Dual-tracer radionuclide imaging in hyperparathyroidism: thallium-201 parathyroid scintigraphy revisited

Qaisar Hussain Siraj 1, Amir Javaid, Nigora Rasulova

Affiliations

01 January 2021

-

doi: 10.1097/MNM.0000000000001295

Abstract

Objectives: Tc-sestamibi is the current radiopharmaceutical of choice for the localization of hyperactive lesions of the parathyroid glands in patients with hyperparathyroidism. However, there are multiple factors that adversely affect the accumulation and retention Tc-sestamibi in the hyperfunctioning parathyroid tissue, resulting in a false-negative scan. The objective of this study was to investigate the possibility of an incremental diagnostic role of thallium-201 parathyroid scintigraphy in patients with presumably false-negative Tc-sestamibi scan results.

Patients and methods: The study comprised of 22 patients including 16 with primary hyperparathyroidism (PHPT) and 6 with secondary hyperparathyroidism where Tc-sestambi scan was initially negative, inconclusive or where additional lesions were suspected on the single-photon computed tomography/computed tomography (SPECT/CT) scan with the CT component identifying lesion(s) without significant Tc-sestamibi uptake.

Results: The results of our study show that in 22 patients (5 male, 17 female; age range 26-81; median age 53.4) further imaging with thallium-201 SPECT/CT scan showed 46.5% additional lesions in patients with hyperparathyroidism caused by an adenomatous or hyperplastic parathyroid lesion. In patients with PHPT caused by an adenomatous or hyperplastic parathyroid lesion, further imaging with thallium-201 showed 59% additional hyperactive parathyroid lesions. In patients with secondary hyperparathyroidism, further imaging with thallium-201 SPECT/CT showed additional 33.3% hyperplastic parathyroid lesions.

Conclusion: The results of this pilot study strongly advocate a role for thallium parathyroid SPECT/CT imaging in patients with primary and secondary hyperparathyroidism where the initial Tc-sestamibi scan is deemed to be false-negative in the presence of biochemical hyperparathyroidism.

Similar articles

A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism: Influence of Thyroid Anomalies.

Michaud L, Balogova S, Burgess A, Ohnona J, Huchet V, Kerrou K, Lefèvre M, Tassart M, Montravers F, Périé S, Talbot JN.Medicine (Baltimore). 2015 Oct;94(41):e1701. doi: 10.1097/MD.0000000000001701.PMID: 26469908 Free PMC article.

Preoperative F-18 fluorocholine PET/CT for the detection of hyperfunctioning parathyroid glands in patients with secondary or tertiary hyperparathyroidism: comparison with Tc-99m sestamibi scan and neck ultrasound.

Chen YH, Chen HT, Lee MC, Liu SH, Wang LY, Lue KH, Chan SC.Ann Nucl Med. 2020 Aug;34(8):527-537. doi: 10.1007/s12149-020-01479-2. Epub 2020 May 20.PMID: 32436180

Usefulness of combination of high-resolution ultrasonography and dual-phase dual-isotope iodine 123/technetium Tc 99m sestamibi scintigraphy for the preoperative localization of hyperplastic parathyroid glands in renal hyperparathyroidism.

Périé S, Fessi H, Tassart M, Younsi N, Poli I, St Guily JL, Talbot JN.Am J Kidney Dis. 2005 Feb;45(2):344-52. doi: 10.1053/j.ajkd.2004.10.021.PMID: 15685513

Detection rate of (99m) Tc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathyroidism: A meta-analysis.

Treglia G, Sadeghi R, Schalin-Jäntti C, Caldarella C, Ceriani L, Giovanella L, Eisele DW.Head Neck. 2016 Apr;38 Suppl 1:E2159-72. doi: 10.1002/hed.24027. Epub 2015 Jul 6.PMID: 25757222 Review.

Sestamibi parathyroid imaging.

McBiles M, Lambert AT, Cote MG, Kim SY.Semin Nucl Med. 1995 Jul;25(3):221-34. doi: 10.1016/s0001-2998(95)80012-3.PMID: 7570042 Review.

Cited by

Semiquantitative assessment of 99mTc-MIBI uptake in parathyroids of secondary hyperparathyroidism patients with chronic renal failure.

Yu D, Zou L, Jin Y, Wei M, Wu X, Zuo L, Wu M, Jiang Y.Front Endocrinol (Lausanne). 2022 Sep 8;13:915279. doi: 10.3389/fendo.2022.915279. eCollection 2022.PMID: 36157459 Free PMC article.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Albright F, Reifenstein EC Jr. The Parathyroid Glands and Metabolic Bone Disease. 1948, Baltimore: Williams & Wilkins
  2.  
    1. Mundy GR, Cove DH, Fisken R. Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet. 1980; 1:1317–1320
  3.  
    1. Bilezikian JP, Silverberg SJ, Gartenberg F. Bilezikian JP. Clinical presentation of primary hyperparathyroidism. The Parathyroids: Basic and Clinical Concepts. 1994, New York: Raven Press457–470
  4.  
    1. Coe FL, Favus MJ. Does mild, asymptomatic hyperparathyroidism require surgery? N Engl J Med. 1980; 302:224–225
  5.  
    1. Javaid A, Siraj QH. Siraj QH. Diagnostic imaging: structural modalities. Radionuclide Parathyroid Imaging: Book and Atlas. 2019, Switzerland: Springer Nature31–40
  6.  
    1. Coakley AJ, Wells CP. Maisey MN, Britton KE, Collier BD, Siraj QH. Parathyroid. Clinical Nuclear Medicine, 1998. 1998, Cambridge: Chapman & Hall381–387
  7.  
    1. Siraj QH, Borisova S, Javaid A. Siraj QH. Parathyroid scintigraphy. Radionuclide Parathyroid Imaging: Book and Atlas. 2019, Switzerland: Springer Nature41–60
  8.  
    1. Siraj QH. Siraj QH. Nuclear medicine cases. Radionuclide Parathyroid Imaging. 2019, Switzerland: Springer67–320
  9.  
    1. Kao A, Shiau YC, Tsai SC, Wang JJ, Ho ST. Technetium-99m methoxyisobutylisonitrile imaging for parathyroid adenoma: relationship to P-glycoprotein or multidrug resistance-related protein expression. Eur J Nucl Med Mol Imaging. 2002; 29:1012–1015
  10.  
    1. Pons F, Torregrosa JV, Fuster D. Biological factors influencing parathyroid localization. Nucl Med Commun. 2003; 24:121–124
  11.  
    1. Mehta NY, Ruda JM, Kapadia S, Boyer PJ, Hollenbeak CS, Stack BC Jr. Relationship of technetium Tc 99m sestamibi scans to histopathological features of hyperfunctioning parathyroid tissue. Arch Otolaryngol Head Neck Surg. 2005; 131:493–498
  12.  
    1. Seki K, Hashimoto K, Hisada T, Maeda M, Satoh T, Uehara Y, et al. A patient with classic severe primary hyperparathyroidism in whom both Tc-99m MIBI scintigraphy and FDG-PET failed to detect the parathyroid tumor. Intern Med. 2004; 43:816–823
  13.  
    1. Sandrock D, Merino MJ, Norton JA, Neumann RD. Ultrastructural histology correlates with results of thallium-201/technetium-99m parathyroid subtraction scintigraphy. J Nucl Med. 1993; 34:24–29
  14.  
    1. Melloul M, Paz A, Koren R, Cytron S, Feinmesser R, Gal R. 99mTc-MIBI scintigraphy of parathyroid adenomas and its relation to tumour size and oxyphil cell abundance. Eur J Nucl Med. 2001; 28:209–213
  15.  
    1. Carpentier A, Jeannotte S, Verreault J, Lefebvre B, Bisson G, Mongeau CJ, Maheux P. Preoperative localization of parathyroid lesions in hyperparathyroidism: relationship between technetium-99m-MIBI uptake and oxyphil cell content. J Nucl Med. 1998; 39:1441–1444
  16.  
    1. Westreich RW, Brandwein M, Mechanick JI, Bergman DA, Urken ML. Preoperative parathyroid localization: correlating false-negative technetium-99m sestamibi scans with parathyroid disease. Laryngoscope. 2003; 13:567–572
  17.  
    1. Bhatnagar A, Vezza PR, Bryan JA, Atkins FB, Ziessman HA. Technetium-99m-sestamibi parathyroid scintigraphy: effect of P-glycoprotein, histology and tumor size on detectability. J Nucl Med. 1998; 39:1617–1620
  18.  
    1. Hetrakul N, Civelek AC, Stagg CA, Udelsman R. In vitro accumulation of technetium-99m-sestamibi in human parathyroid mitochondria. Surgery. 2001; 130:1011–1018
  19.  
    1. Piñero A, Rodriguez JM, Ortiz S, Soria T, Bermejo J, Claver MA, et al. Relation of biochemical, cytologic, and morphologic parameters to the result of gammagraphy with technetium 99m sestamibi in primary hyperparathyroidism. Otolaryngol Head Neck Surg. 2000; 122:851–855
  20.  
    1. Erbil Y, Kapran Y, Işsever H, Barbaros U, Adalet I, Dizdaroğlu F, et al. The positive effect of adenoma weight and oxyphil cell content on preoperative localization with 99mTc-sestamibi scanning for primary hyperparathyroidism. Am J Surg. 2008; 195:34–39
  21.  
    1. Mori K, Yamaguchi T, Maeda M. Mechanism of 201 thallium-chloride uptake in tumor cells and its relationship to potassium channels. Neurol Res. 2016; 20:19–22
  22.  
    1. Sisson JC, Beierwalters WH. Radiocyanocobalamine (Co57 B12) concentration in the parathyroid glands. J Nucl Med. 1962; 3:160–166
  23.  
    1. Potchen EJ, Adelstein SJ, Delay JB. Radioisotopic localization of the overactive human parathyroid. AJR. 1965; 93:955–961
  24.  
    1. Ferlin G, Borsato N, Camerani M, Conte N, Zotti D. New perspectives in localizing enlarged parathyroids by technetium-thallium subtraction scan. J Nucl Med. 1983; 24:438–441
  25.  
    1. Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017; 28:1–19
  26.  
    1. Coakley AJ, Kettle AG, Wells CP, O’Doherty MJ, Collins RE. 99Tcm sestamibi–a new agent for parathyroid imaging. Nucl Med Commun. 1989; 10:791–794
  27.  
    1. Wei JP, Burke GJ, Mansberger AR Jr. Preoperative imaging of abnormal parathyroid glands in patients with hyperparathyroid disease using combination Tc-99m-pertechnetate and Tc-99m-sestamibi radionuclide scans. Ann Surg. 1994; 219:568–572; discussion 572

Page Navigation